As part of our ongoing dialogue around clinical care pathways and the complex of metabolic diseases, SurfingNASH dedicates a session to focus on the key relationship and interplay between endocrinology and hepatology.
This topic rings familiar in the Rising Tide series, our podcast for frontline education, where Ken Cusi often notes the need for endocrinologists to become comfortable diagnosing Fatty Liver disease (and prescribing pioglitazone) and for hepatologists to become more comfortable prescribing GLP-1s. To expand on these critical ideas with the SurfingNASH community, Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy, Professor of Nutrition and Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital, Hospices Civils de Lyon (France). Cyrielle is an expert in the clinical care of metabolic disease, including type 2 diabetes, obesity and NAFLD, and is leading a clinical and research program focused on metabolic liver disease at the Lyon Hepatology Institute.
New to the podcast, Cyrielle takes a moment to outline her career trajectory and how she became interested in Fatty Liver disease and its growing area of overlap within the wider scope of medical care. From here, Roger describes overarching questions that the episode aims to cover:
What does the interaction between endocrinologists and hepatologists look like from their relative perspectives?
In practical terms, how does each approach care pathways, referrals and collaboration?
What about either speciality would be key for the other to learn more about, develop or integrate?
Jörn first comments on the value of deploying the NITs developed by the hepatology community to endocrinology clinics. He notes the practical barriers which could hinder uptake and utilization as many may have lingering questions. How will this make a difference in the management of my patient? How do I potentially deal with a positive test? Do I need to refer this patient and what if I have nobody to refer to? Jörn looks to Cyrielle for advice on how to entice endocrinologists to align with the need of identifying Fatty Liver disease in at-risk populations. Among other insights, Cyrielle underscores the importance behind raising awareness with endocrinologist colleagues that patients in routine screening are regularly diagnosed with advanced fibrosis and cirrhosis in the absence of symptoms.
If you enjoy the episode, have questions or interest around endocrinology and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!
